Gene: DRD5

1816
DBDR|DRD1B|DRD1L2
dopamine receptor D5
protein-coding
4p16.1
Ensembl:ENSG00000169676 MIM:126453 Vega:OTTHUMG00000128489 UniprotKB:P21918
NG_012024.1
PubMed
CD|ND|AD
8   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.279e-1 (AD)  5.898e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GALNT140.831
GRIK30.806
ADTRP0.799
SLC7A40.792
CNIH30.787
CPNE70.787
CLSTN20.786
NRG10.785
IL12RB20.777
RAB3B0.775

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PRKD3-0.574
EPS8-0.568
RBPMS-0.568
GNG11-0.559
WWTR1-0.559
RAB13-0.555
YES1-0.548
TEAD3-0.547
RNF135-0.547
CLEC2B-0.546

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00246ZiprasidoneSmall Molecule146939-27-7ApprovedTarget
DB00248CabergolineSmall Molecule81409-90-7ApprovedTarget
DB00268RopiniroleSmall Molecule91374-21-9Approved|InvestigationalTarget
DB00334OlanzapineSmall Molecule132539-06-1Approved|InvestigationalTarget
DB00408LoxapineSmall Molecule1977-10-2ApprovedTarget
DB00413PramipexoleSmall Molecule104632-26-0Approved|InvestigationalTarget
DB00477ChlorpromazineSmall Molecule50-53-3Approved|InvestigationalTarget
DB00589LisurideSmall Molecule18016-80-3Approved|InvestigationalTarget
DB00714ApomorphineSmall Molecule58-00-4Approved|InvestigationalTarget
DB00800FenoldopamSmall Molecule67227-56-9ApprovedTarget
DB00988DopamineSmall Molecule51-61-6ApprovedTarget
DB01038CarphenazineSmall Molecule2622-30-2WithdrawnTarget
DB01186PergolideSmall Molecule66104-22-1Approved|Investigational|WithdrawnTarget
DB01200BromocriptineSmall Molecule25614-03-3Approved|InvestigationalTarget
DB01224QuetiapineSmall Molecule111974-69-7ApprovedTarget
DB01235LevodopaSmall Molecule59-92-7ApprovedTarget
DB01238AripiprazoleSmall Molecule129722-12-9Approved|InvestigationalTarget
DB01403MethotrimeprazineSmall Molecule60-99-1Approved|InvestigationalTarget
DB01624ZuclopenthixolSmall Molecule53772-83-1Approved|InvestigationalTarget
DB05271RotigotineSmall Molecule99755-59-6ApprovedTarget
DB00248CabergolineSmall Molecule81409-90-7ApprovedTarget
DB00334OlanzapineSmall Molecule132539-06-1Approved|InvestigationalTarget
DB00370MirtazapineSmall Molecule85650-52-8ApprovedTarget
DB00408LoxapineSmall Molecule1977-10-2ApprovedTarget
DB00458ImipramineSmall Molecule50-49-7ApprovedTarget
DB00477ChlorpromazineSmall Molecule50-53-3Approved|InvestigationalTarget
DB00555LamotrigineSmall Molecule84057-84-1Approved|InvestigationalTarget
DB00568CinnarizineSmall Molecule298-57-7Approved|InvestigationalTarget
DB00696ErgotamineSmall Molecule113-15-5ApprovedTarget
DB00726TrimipramineSmall Molecule739-71-9ApprovedTarget
DB00988DopamineSmall Molecule51-61-6ApprovedTarget
DB06148MianserinSmall Molecule24219-97-4Approved|InvestigationalTarget
DB09097QuinagolideSmall Molecule87056-78-8Approved|InvestigationalTarget
DB09225ZotepineSmall Molecule26615-21-4Approved|Investigational|WithdrawnTarget
ID Drug Name Action PubMed
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of DRD5 protein"26215117
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of DRD5 mRNA"21346803
C4098747-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine"7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine binds to and results in decreased activity of DRD5 protein"12447918|1518390
C4098747-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine"7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine binds to DRD5 protein"21888437
C065380A 68930A 68930 binds to and results in increased activity of DRD5 protein14960337
C065380A 68930[A 68930 binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine14960337
C095427A 86929A 86929 promotes the reaction [DRD5 protein results in increased chemical synthesis of Cyclic AMP]8558425
C095427A 86929A 86929 binds to DRD5 protein8558425
C095427A 86929A 86929 results in increased activity of DRD5 protein8558425
D000242Cyclic AMPA 86929 promotes the reaction [DRD5 protein results in increased chemical synthesis of Cyclic AMP]8558425
D000336AerosolsAerosols results in increased expression of DRD5 mRNA25265048
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of DRD5 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of DRD5 gene28458013
D000643Ammonium ChlorideAmmonium Chloride affects the expression of DRD5 mRNA16483693
D000661Amphetamine[A 68930 binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine14960337
D000661Amphetamine[dihydrexidine binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine14960337
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of DRD5 mRNA24449571
C006780bisphenol Abisphenol A results in decreased expression of DRD5 mRNA25181051|2614162
C018475butyraldehydebutyraldehyde results in increased expression of DRD5 mRNA26079696
D002104CadmiumCadmium results in decreased expression of DRD5 mRNA24376830
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in increased expression of DRD5 mRNA21472459
D020111Chlorodiphenyl (54% Chlorine)Quercetin inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in increased expression of DRD5 mRNA]21472459
C018021cobaltous chloridecobaltous chloride results in increased expression of DRD5 mRNA19376846
D003042CocaineCocaine affects the expression of DRD5 mRNA20187946
D019327Copper SulfateCopper Sulfate results in increased expression of DRD5 mRNA19549813
D003471CuprizoneCuprizone results in decreased expression of DRD5 mRNA26577399
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of DRD5 mRNA23640034
D001728DicumarolDicumarol results in increased expression of DRD5 mRNA18522901
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of DRD5 mRNA21658437
C061532dihydrexidinedihydrexidine binds to and results in increased activity of DRD5 protein14960337
C061532dihydrexidine[dihydrexidine binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine14960337
D004298DopamineDopamine results in increased expression of DRD5 mRNA18522901
C058081ecopipamecopipam binds to and results in decreased activity of DRD5 protein10591286
D005419FlavonoidsFlavonoids results in decreased expression of DRD5 mRNA18035473
D005472FluorouracilDRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]17327601
D002955LeucovorinDRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]17327601
C069837fullerene C60fullerene C60 results in decreased expression of DRD5 mRNA19167457
C051890irinotecanDRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]17327601
C045463leflunomideleflunomide results in increased expression of DRD5 mRNA28988120
D008344Maneb[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA23017109
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of DRD5 mRNA"20188158
D008825MiconazoleMiconazole results in increased expression of DRD5 mRNA22262564
C028007nickel monoxidenickel monoxide results in decreased expression of DRD5 mRNA19167457
D010269Paraquat[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA23017109
D052638Particulate Matter[Particulate Matter co-treated with Volatile Organic Compounds] results in increased expression of DRD5 mRNA25265048
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid affects the expression of DRD5 mRNA26686188
D010627PhenethylaminesPhenethylamines analog binds to DRD5 protein16539400
D010936Plant ExtractsPlant Extracts results in decreased expression of DRD5 mRNA23557933
D011192Potassium DichromatePotassium Dichromate results in increased expression of DRD5 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of DRD5 mRNA24780913
D011794QuercetinQuercetin inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in increased expression of DRD5 mRNA]21472459
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride results in increased expression of DRD5 mRNA19429434
D012524SarinSarin results in increased expression of DRD5 mRNA19522546
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of DRD5 mRNA23806026
D013629TamoxifenTamoxifen affects the expression of DRD5 mRNA14699072
D013629TamoxifenTamoxifen results in increased expression of DRD5 mRNA19429434
D013806TheophyllineTheophylline results in increased expression of DRD5 mRNA18951874
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of DRD5 mRNA"26179874
D014635Valproic AcidValproic Acid results in increased methylation of DRD5 gene29154799
D055549Volatile Organic Compounds[Particulate Matter co-treated with Volatile Organic Compounds] results in increased expression of DRD5 mRNA25265048

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001588dopamine neurotransmitter receptor activity, coupled via Gs-IBA21873635  
GO:0001588dopamine neurotransmitter receptor activity, coupled via Gs-TAS9457173  
GO:0001965G-protein alpha-subunit binding-IBA21873635  
GO:0004952dopamine neurotransmitter receptor activity-IDA1826762  
GO:0035240dopamine binding-IBA21873635  
GO:0035240dopamine binding-IDA1826762  
GO ID GO Term Qualifier Evidence PubMed
GO:0001963synaptic transmission, dopaminergic-NAS11036203  
GO:0001975response to amphetamine-IEA-  
GO:0001992regulation of systemic arterial blood pressure by vasopressin-IEA-  
GO:0001994norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure-IEA-  
GO:0006874cellular calcium ion homeostasis-TAS9457173  
GO:0007186G-protein coupled receptor signaling pathway-TAS-  
GO:0007189adenylate cyclase-activating G-protein coupled receptor signaling pathway-IDA11500503  
GO:0007190activation of adenylate cyclase activity-TAS9457173  
GO:0007191adenylate cyclase-activating dopamine receptor signaling pathway-IBA21873635  
GO:0007191adenylate cyclase-activating dopamine receptor signaling pathway-IDA1826762  18403039  
GO:0007268chemical synaptic transmission-NAS7727453  
GO:0008306associative learning-IEA-  
GO:0019226transmission of nerve impulse-IEA-  
GO:0033861negative regulation of NAD(P)H oxidase activity-IDA16352863  
GO:0042060wound healing-IEA-  
GO:0042220response to cocaine-IEA-  
GO:0045762positive regulation of adenylate cyclase activity-NAS7727453  
GO:0045776negative regulation of blood pressure-IEA-  
GO:0045924regulation of female receptivity-IEA-  
GO:0046960sensitization-IEA-  
GO:0060158phospholipase C-activating dopamine receptor signaling pathway-TAS9457173  
GO:0060292long term synaptic depression-IEA-  
GO:0071870cellular response to catecholamine stimulus-IDA18403039  
GO:0072593reactive oxygen species metabolic process-IDA16352863  
GO ID GO Term Qualifier Evidence PubMed
GO:0005622intracellular-IEA-  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-IDA10531415  11500503  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-NAS1826762  
GO:0005887integral component of plasma membrane-TAS9457173  
GO:0016021integral component of membrane-IBA21873635  
GO:0031526brush border membrane-IEA-  
GO:0060170ciliary membrane-IDA20531939  
GO:0097730non-motile cilium-IDA20531939  
KEGG ID KEGG Term
hsa04020Calcium signaling pathway
hsa04080Neuroactive ligand-receptor interaction
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-373076Class A/1 (Rhodopsin-like receptors)TAS
R-HSA-375280Amine ligand-binding receptorsTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-390651Dopamine receptorsTAS
R-HSA-418555G alpha (s) signalling eventsTAS
R-HSA-500792GPCR ligand bindingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
11353446An association study of DRD5 with smoking initiation and progression to nicotine dependence. (2001 Apr 8)Sullivan PFAm J Med Genet
9686426Chromosome 4 workshop. (1998 Summer)Kennedy JLPsychiatr Genet
17579368Testing for gene x environment interaction effects in attention deficit hyperactivity disorder and associated antisocial behavior. (2008 Jan 5)Langley KAm J Med Genet B Neuropsychiatr Genet
25875614Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans. (2015 May)Levran OAnn Hum Genet
22309839Association study of 45 candidate genes in nicotine dependence in Han Chinese. (2012 May)Wei JAddict Behav
19179847Genetics of dopamine receptors and drug addiction: a comprehensive review. (2009 Feb)Le Foll BBehav Pharmacol
174669465' UTR polymorphism of dopamine receptor D1 (DRD1) associated with severity and temperament of alcoholism. (2007 Jun 15)Kim DJBiochem Biophys Res Commun
21083670Limited associations of dopamine system genes with alcohol dependence and related traits in the Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD). (2011 Feb)Hack LMAlcohol Clin Exp Res